Environment, Pathogens, and Host Interactions in Melioidosis

This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems:

• Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand (MORU);
• Mahosot Hospital, Vientiane, Lao PDR (LOMWRU); and
• Angkor Hospital for Children, Siem Reap, Cambodia (COMRU).

In addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.

Participant Recruitment and Follow-up

Hospital cohort:

Patients with melioidosis will be recruited at all three hospital sites. The study plans to recruit 1,000 patients, who will be followed longitudinally at six time points: Day 0 (admission), Days 3 and 7 (acute phase), and Days 30, 180, and 365 (recovery phase).

Clinical data collected will include demographic characteristics, underlying comorbidities, environmental exposures, lifestyle and behavioural factors, treatment history, patient-reported medication adherence, and follow-up outcomes.

Healthy controls:

Each patient will be matched with a healthy control recruited within two weeks of diagnosis, based on age, sex, and village of residence. Controls will have no current symptoms or prior history of melioidosis. They will provide a single blood sample at enrolment for DNA extraction and antibody profiling and will be followed up by telephone on Days 180 and 365.

Community cohort:

To complement hospital-based data and to identify subclinical infections, intensive community surveillance will be conducted in the Sandbox Village, a high-incidence area within the Ubon Ratchathani region. All residents (approximately 400 individuals) will be enrolled. DNA samples will be collected at baseline, and serum samples will be obtained every two months over a 42-month period, either at participants' homes or at a central village location, to measure antibody responses to Burkholderia pseudomallei as a proxy for exposure.

Community cohort:

To complement hospital-based data and to identify subclinical infections, intensive community surveillance will be conducted in the Sandbox Village, a high-incidence area within the Ubon Ratchathani region. All residents (approximately 400 individuals) will be enrolled. DNA samples will be collected at baseline, and serum samples will be obtained every two months over a 42-month period, either at participants' homes or at a central village location, to measure antibody responses to Burkholderia pseudomallei as a proxy for exposure.

Inclusion criteria

for melioidosis patients:

• Age ≥20 years
• Positive for Burkholderia pseudomallei from any clinical samples
• Resident of the study area for at least two years, including the follow-up period
• Willing to participate and give informed consent.

Inclusion criteria

for healthy controls:

• Age ≥20 years
• Currently healthy as judged by study doctor
• Resident of the study area for at least two years, including the follow-up period
• Willing to participate and give informed consent.

Inclusion criteria

for sandbox residents:

• Age ≥20 years
• Resident of the study area for at least two years, including the follow-up period
• Willing to participate and give informed consent.

Exclusion criteria

for melioidosis patients:

• Current tuberculosis (TB) or TB treatment within the past six months
• Documented HIV infection or use of immunosuppressive therapy in the past 12 months

Exclusion criteria

for healthy controls:

• History of melioidosis
• Significant acute illness
• Current fever or soft tissue infection

Exclusion criteria

for sandbox residents

-N/A